Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tenvir is an antiviral medication containing tenofovir disoproxil fumarate (TDF), a nucleotide reverse transcriptase inhibitor (NRTI). It is primarily used for the treatment of HIV-1 infection and chronic hepatitis B virus (HBV) infection. As a prodrug, it is converted intracellularly to tenofovir diphosphate, which acts as an analog of deoxyadenosine 5'-triphosphate. It competes with the natural substrate for incorporation into viral DNA via the HIV-1 reverse transcriptase or HBV polymerase enzymes. Once incorporated, it causes viral DNA chain termination because it lacks the 3'-hydroxyl group necessary for further phosphodiester bond formation. Tenvir is distributed by Magicine Pharma and is part of the ARECHAR product portfolio, serving as a critical component of antiretroviral therapy (ART) to reduce viral load and improve immune function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tenvir.